The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Rakuten Medical initiates global phase 3 trial of ASP-1929 photoimmunotherapy in combo with pembrolizumab to treat recurrent head and neck cancer: United States Saturday, January ...

Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led to clinically meaningful improvement in ...

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

The immune checkpoint inhibitor pembrolizumab may reduce this risk. New research findings are summarized in a short video.

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches ...

Bicycle Therapeutics (BCYC) announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously ...

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

Host Dr. Rafeh Naqash and Drs. Bedard and Hernando Calvo discuss how combined transcriptome and ctDNA longitudinal analysis associates with pembrolizumab outcomes. Today we are excited to be joined by ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...